AI-generated analysis. Always verify with the original filing.
Boundless Bio, Inc. announced Q4 and full year 2025 financial results with net loss of $12.9 million and $58.2 million respectively, cash of $107.6 million providing runway into second half of 2028, and KOMODO-1 trial of BBI-940 open for enrollment. Christine Brennan, Ph.D. resigned from the Board effective March 3, 2026, for a new role at Johnson & Johnson Development Corporation with no disagreements.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 9, 2026, Boundless Bio, Inc. (the Company) issued a press release announcing its financial results for t
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Effective Marc
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Issued on March 9, 2026 104 Cover Page Interactive Data File (emb
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $9.8K | GAAP |
| Research and Development Expenses | $44.8K | GAAP |
| General and Administrative Expenses | $4.2K | GAAP |
| General and Administrative Expenses | $18.7K | GAAP |
| Net Loss | $12.9K | GAAP |
| Net Loss | $58.2K | GAAP |
| Net Loss per Share, Basic and Diluted | $-0.58 | GAAP |
| Net Loss per Share, Basic and Diluted | $-2.60 | GAAP |
Christine Brennan, Ph.D.
Effective: 2026-03-03
assuming a new role at Johnson & Johnson Development Corporation